好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Role of Plasmapheresis In Pediatric Antibody- Negative Autoimmune Encephalitis
Autoimmune Neurology
P2 - Poster Session 2 (9:00 AM-3:00 PM)
013

We show the efficacy and relative safety of plasmapheresis as a treatment option for antibody negative AIE in children.

Plasmapheresis is well established therapy for antibody mediated autoimmune encephalitis (AIE). In patients with no identified antibody, the role of plasmapheresis is unclear. Starting plasmapheresis becomes even more controversial in children with antibody negative AIE
An IRB approved chart review was conducted on patients <18 years diagnosed with autoimmune encephalitis. A retrospective analysis of response to plasmapheresis and long term follow up was conducted on patients that did not have an identified antibody.  

52 patients <18 years were diagnosed with autoimmune encephalitis, 14 (26.9%) of these tested negative for antibodies. 2 (14%) patients received only steroids, while all others received Steroids plus IVIG. 7 (58%) patients received rituximab for poor response/relapse following Steroids plus IVIG. Of these, 3 (43%) patients further underwent plasmapheresis for presumed refractory AIE. All patients had improvement after plasmapheresis and remained symptom free, including seizure freedom, at 2 year follow up. One patient needed repeat plasmapheresis for presumed relapse. No adverse effects reported.

Several studies have shown that timely delivery of immunotherapies is crucial and delay in treatment due to negative autoantibodies can lead to poorer outcomes. Plasmapheresis is safe and should be considered for refractory/relapsing AIE in children, even in the absence of an identified antibody. Larger studies in future can help solidify the findings from our cohort. 
Authors/Disclosures
Geetanjali S. Rathore, MD, FAAN (Childrens NEBRASKA)
PRESENTER
Dr. Rathore has nothing to disclose.